Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Takeda expands collaboration to develop antibody

Takeda expands collaboration to develop antibody

10th February 2009

Takeda Pharmaceutical has expanded its collaboration with Xoma in an attempt to move forward with its work on creating an antibody product pipeline.

The company announced today it will now have access to various technologies and data management systems, which are aimed at providing the project with further capabilities aside from Takeda’s own resources.

As part of the deal, Xoma will be given $29 million (19.6 million pounds) as an expansion fee and the possibility of later milestone payments and royalties.

Steven Engle is chairman and chief executive officer at the firm and said it was “pleased” to further the collaboration with Takeda.

“Antibodies are playing an increasingly important role in the future of patient care,” he remarked.

“Innovation in antibody technology is accelerating to meet this need. This expansion is evidence of Xoma’s leadership in the field of antibody discovery and development.”

Last month, Takeda confirmed the start of two phase III trials undertaken by its wholly-owned subsidiary Millennium Pharmaceuticals.

The studies are investigating vedolizumab for the treatment of Crohn’s disease and ulcerative colitis.

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.